Cargando…

Type I interferon in organ-targeted autoimmune and inflammatory diseases

A significant role for IFNα in the pathogenesis of systemic lupus erythematosus is well supported, and clinical trials of anti-IFNα monoclonal antibodies are in progress in this disease. In other autoimmune diseases characterized by substantial inflammation and tissue destruction, the role of type I...

Descripción completa

Detalles Bibliográficos
Autor principal: Crow, Mary K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991778/
https://www.ncbi.nlm.nih.gov/pubmed/21303493
http://dx.doi.org/10.1186/ar2886
_version_ 1782192633187139584
author Crow, Mary K
author_facet Crow, Mary K
author_sort Crow, Mary K
collection PubMed
description A significant role for IFNα in the pathogenesis of systemic lupus erythematosus is well supported, and clinical trials of anti-IFNα monoclonal antibodies are in progress in this disease. In other autoimmune diseases characterized by substantial inflammation and tissue destruction, the role of type I interferons is less clear. Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature similar to but less intense than that seen in patients with lupus. In both of those diseases, presence of the interferon signature has been associated with more significant clinical manifestations. At the same time, evidence supports an anti-inflammatory and beneficial role of IFNβ locally in the joints of patients with rheumatoid arthritis and in murine arthritis models, and many patients with multiple sclerosis show a clinical response to recombinant IFNβ. As can also be proposed for type I diabetes mellitus, type I interferon appears to contribute to the development of autoimmunity and disease progression in multiple autoimmune diseases, while maintaining some capacity to control established disease - particularly at local sites of inflammation. Recent studies in both rheumatoid arthritis and multiple sclerosis suggest that quantification of type I interferon activity or target gene expression might be informative in predicting responses to distinct classes of therapeutic agents.
format Text
id pubmed-2991778
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29917782010-11-26 Type I interferon in organ-targeted autoimmune and inflammatory diseases Crow, Mary K Arthritis Res Ther Review A significant role for IFNα in the pathogenesis of systemic lupus erythematosus is well supported, and clinical trials of anti-IFNα monoclonal antibodies are in progress in this disease. In other autoimmune diseases characterized by substantial inflammation and tissue destruction, the role of type I interferons is less clear. Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature similar to but less intense than that seen in patients with lupus. In both of those diseases, presence of the interferon signature has been associated with more significant clinical manifestations. At the same time, evidence supports an anti-inflammatory and beneficial role of IFNβ locally in the joints of patients with rheumatoid arthritis and in murine arthritis models, and many patients with multiple sclerosis show a clinical response to recombinant IFNβ. As can also be proposed for type I diabetes mellitus, type I interferon appears to contribute to the development of autoimmunity and disease progression in multiple autoimmune diseases, while maintaining some capacity to control established disease - particularly at local sites of inflammation. Recent studies in both rheumatoid arthritis and multiple sclerosis suggest that quantification of type I interferon activity or target gene expression might be informative in predicting responses to distinct classes of therapeutic agents. BioMed Central 2010 2010-08-25 /pmc/articles/PMC2991778/ /pubmed/21303493 http://dx.doi.org/10.1186/ar2886 Text en Copyright ©2010 BioMed Central Ltd
spellingShingle Review
Crow, Mary K
Type I interferon in organ-targeted autoimmune and inflammatory diseases
title Type I interferon in organ-targeted autoimmune and inflammatory diseases
title_full Type I interferon in organ-targeted autoimmune and inflammatory diseases
title_fullStr Type I interferon in organ-targeted autoimmune and inflammatory diseases
title_full_unstemmed Type I interferon in organ-targeted autoimmune and inflammatory diseases
title_short Type I interferon in organ-targeted autoimmune and inflammatory diseases
title_sort type i interferon in organ-targeted autoimmune and inflammatory diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991778/
https://www.ncbi.nlm.nih.gov/pubmed/21303493
http://dx.doi.org/10.1186/ar2886
work_keys_str_mv AT crowmaryk typeiinterferoninorgantargetedautoimmuneandinflammatorydiseases